Results 291 to 300 of about 905,763 (403)

Cardiac rhythm devices in heart failure with reduced ejection fraction – role, timing, and optimal use in contemporary practice. European Journal of Heart Failure expert consensus document

open access: yesEuropean Journal of Heart Failure, EarlyView.
Abstract Guidelines for management of heart failure with reduced ejection fraction (HFrEF) emphasize personalized care, patient engagement, and shared decision‐making. Medications and cardiac rhythm management (CRM) devices are recommended with a high level of evidence. However, there are significant disparities: patients who could benefit from devices
Biykem Bozkurt   +15 more
wiley   +1 more source

Heart on Fire: Unmasking <i>RyR2</i> Mutation in Stress-Induced Ventricular Arrhythmias. [PDF]

open access: yesMethodist Debakey Cardiovasc J
Sharma V   +5 more
europepmc   +1 more source

Cardioprotective effects of semaglutide on isolated human ventricular myocardium

open access: yesEuropean Journal of Heart Failure, EarlyView.
Semaglutide reduces late sodium current (INa) and diastolic calcium (Ca) sparks in human cardiomyocytes from aortic stenosis (AS) and end‐stage heart failure with reduced ejection fraction (HFrEF) patients, thereby increasing Ca transients. Improved Ca storage may underly the enhanced contractility of human cardiomyocytes upon semaglutide.
Thomas Krammer   +16 more
wiley   +1 more source

The use of left ventricular ejection fraction in the diagnosis and management of heart failure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC, the Heart Failure Society of America (HFSA), and the Japanese Heart Failure Society (JHFS)

open access: yesEuropean Journal of Heart Failure, EarlyView.
Abstract This clinical consensus statement revisits the role of left ventricular ejection fraction (LVEF) as a measurement of cardiac function, a prognostic marker and a major criterion to classify patients with heart failure, and gives new advice for clinical practice.
Giuseppe M.C. Rosano   +20 more
wiley   +1 more source

A new application of computed tomography: stereotactic radiotherapy in the treatment of ventricular arrhythmias. [PDF]

open access: yesEur Heart J Suppl
Mancini ME   +9 more
europepmc   +1 more source

Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death across cardio‐kidney‐metabolic diseases: A meta‐analysis of randomized clinical trials

open access: yesEuropean Journal of Heart Failure, EarlyView.
Abstract Aims Sudden cardiac death (SCD) is a prevalent cause of mortality among patients with cardio‐kidney‐metabolic (CKM) diseases. Mineralocorticoid receptor antagonists (MRAs) reduce the risk of SCD in patients with left ventricular dysfunction, but it is unclear if similar effects are expected across different CKM risk populations irrespective of
Pedro Marques   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy